Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2336076 | 1.00 | NAMPT (0.42) | NAMPTTBXAS1CHRNB2CHRNA4TBXA2R | |
| SCHEMBL5669033 | 1.00 | NAMPT (0.42) | NAMPTTBXAS1CHRNB2CHRNA4TBXA2R | |
| SCHEMBL5668642 | 0.88 | SMN1; SMN2 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2333016 | 0.88 | SMN1; SMN2 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2333022 | 0.88 | SMN1; SMN2 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2333018 | 0.88 | SMN1; SMN2 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2333014 | 0.88 | SMN1; SMN2 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2338575 | 0.88 | SMN1; SMN2 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2339305 | 0.86 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2332985 | 0.86 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | claimed |
| US-8193389-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | claimed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | claimed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20120270902-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8193389-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2374792-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-2360142-A1 | N-substituted benzene sulfonamides | Elan Pharmaceuticals Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-1723102-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050245573-A1 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090296-A2 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245573-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | NAMPT 1917/4885TBXAS1 158/4885CHRNB2 223/4885 |
| US-20120270902-A1 | N-substituted benzene sulfonamides | PSEN1, PSEN2, BCHE | NAMPT 1917/4885TBXAS1 158/4885CHRNB2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.